In the high-stakes race to develop life-changing therapies, sound strategy is as critical as sound science. GIC provides the definitive market intelligence that pharma leaders, biotech innovators, and life science investors need to navigate the complexities of R&D, clinical trials, and commercialization.
Drug Discovery, Clinical Development, Cell & Gene Therapy, Biologics, Small Molecules, CDMOs
Pipeline Analysis, Clinical Trial Benchmarking, Market Access & Reimbursement, M&A Due Diligence
PhDs in Biology & Chemistry, Clinical Trial Experts, Regulatory Affairs Specialists, Healthcare Economists
Annual Deep-Dive Reports, Quarterly Pipeline Updates, Real-Time Clinical Trial Data Alerts
Life science leaders partner with GIC to achieve mission-critical objectives:
The industry faces immense scientific and commercial challenges:
We track thousands of ongoing clinical trials, using AI to analyze protocols, predict success rates, and benchmark performance against industry standards.
Our team of PhDs analyzes scientific publications and patent filings to map the competitive landscape and identify emerging platform technologies before they are widely known.
We synthesize data on pricing, reimbursement, and health technology assessments (HTA) to create robust commercial forecasts and market access strategies.
Each report is a complete strategic playbook, covering the entire life sciences value chain from discovery to commercialization.
5-year revenue forecasts for key disease areas like oncology, immunology, and CNS.
Comprehensive tracking of assets from preclinical stages through Phase III.
Deep dives into cell therapy, gene editing (CRISPR), mRNA, and antibody platforms.
Comparative analysis of development strategies, costs, and market potential.
Real-time analysis of deal structures, valuations, and strategic rationales.
Analysis of approval trends, orphan drug designations, and accelerated pathways.
Insights on payer negotiations, formulary placement, and value-based pricing.
Analysis of biomanufacturing capacity, technology trends, and leading CDMO partners.
Forecasting revenue erosion from patent cliffs and biosimilar competition.
Tracking the impact of AI on target identification, trial design, and R&D productivity.
Full access to our raw data on clinical trials, company pipelines, and market models.
Clear guidance for R&D, business development, and commercial leaders.
"The median M&A premium for preclinical biotech assets has increased to 120%, up from 75% two years ago, signaling intense competition among large pharma to acquire novel platform technologies."
Lead Analyst, Life Science M&A, GIC
The probability of success for a typical oncology drug moving from Phase I to approval is just 5.1%. However, for therapies using validated biomarkers, that rate jumps to 26.3%.
GIC Clinical Success Rate Model, Q2 2025
Antibody-Drug Conjugates (ADCs) now represent the fastest-growing class of cancer therapeutics, with a forecasted market size of $30 billion by 2029.
GIC Oncology Market Forecast, Q2 2025
Over 70% of newly approved drugs in the last year received at least one form of expedited review from the FDA (e.g., Breakthrough, Fast Track).
GIC Regulatory Intelligence Tracker, Q1 2025
Connect with a GIC analyst to discuss our syndicated Pharma & Biotech reports or to commission a bespoke research project on your specific therapeutic area, asset, or strategic challenge.
Speak with a Life Sciences Analyst